Of the 682 patients (68.5% of the total sample) whose HER2 status was negative or unknown and were receiving active 1L treatment, the mean (SD) age was 64.6 (9.5) years, 70% were male, and 61% were diagnosed with GC, 28% with GEJC, and 11% with EAC. The gene discussed is ERBB2; the disease is gastric cancer.